Myriad Genetics Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Myriad Genetics Inc 公司

Myriad Genetics, Inc. 是一家基因检测和精准医疗公司。该公司开发并提供基因检测，帮助评估患病或疾病进展的风险，并指导各个医学专业的治疗决策，其中基因洞察可以显著改善患者护理并降低医疗成本。该公司专注于三个关键领域，在这些领域拥有专门的产品、能力和专业知识：肿瘤学、女性健康和心理健康。在肿瘤学领域，该公司为癌症患者提供检测，并提供与相应药物和治疗配合使用的伴随诊断测试。它还提供 SneakPeek 早期性别 DNA 测试，可以在怀孕六周后揭示婴儿的性别。该公司的检测产品包括 MyRisk、BRACAnalysis、BRACAnalysis CDx、MyChoice CDx、Prolaris、Foresight、Prequel、Precis Tumor Test、Precise Liquid Test、SneakPeek 和 GeneSight 等。

公司简介

公司代码MYGN

公司名称Myriad Genetics Inc

上市日期Oct 06, 1995

CEOMr. Samraat S. (Sam) Raha

员工数量2700

证券类型Ordinary Share

年结日Oct 06

公司地址322 North 2200 West

城市SALT LAKE CITY

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编84116

电话18015843600

网址https://myriad.com/

公司代码MYGN

上市日期Oct 06, 1995

CEOMr. Samraat S. (Sam) Raha

公司高管

名称

名称/职务

职务

持股

持股变动

Mr. Brian Donnelly

Chief Commercial Officer

397.53K

--

Mr. Mark S. Verratti

Chief Operating Officer and Chief Commercial Officer

221.65K

-11.52%

Dr. Lee Nisley Newcomer, M.D.

Independent Director

132.14K

+60.47%

Ms. Margaret (Maggie) Ancona

Senior Vice President, Chief of Staff

128.68K

+56.61%

Ms. Rashmi Kumar

Independent Director

127.19K

+64.34%

Ms. Shereen Solaiman

Chief People Officer

110.96K

+98.89%

Mr. Benjamin Richard (Ben) Wheeler

Chief Financial Officer

95.21K

--

Dr. Dale Muzzey

Chief Scientific Officer

45.88K

-46.96%

Ms. S. Louise Phanstiel, CPA

Independent Chairman of the Board

--

Mr. Matt Scalo

Investor Relations

--

名称

名称/职务

职务

持股

持股变动

Mr. Brian Donnelly

Chief Commercial Officer

397.53K

--

Mr. Mark S. Verratti

Chief Operating Officer and Chief Commercial Officer

221.65K

-11.52%

Dr. Lee Nisley Newcomer, M.D.

Independent Director

132.14K

+60.47%

Ms. Margaret (Maggie) Ancona

Senior Vice President, Chief of Staff

128.68K

+56.61%

Ms. Rashmi Kumar

Independent Director

127.19K

+64.34%

Ms. Shereen Solaiman

Chief People Officer

110.96K

+98.89%

收入明细

单位: USD更新时间: 7月6日周日

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

业务USD

名称

营收

占比

Hereditary Cancer

86.30M

44.05%

Prenatal

49.30M

25.17%

Pharmacogenomics

31.00M

15.82%

Tumor Profiling

29.30M

14.96%

地区USD

名称

营收

占比

United States

181.60M

92.70%

Rest of world

14.30M

7.30%

业务

地区

业务USD

名称

营收

占比

Hereditary Cancer

86.30M

44.05%

Prenatal

49.30M

25.17%

Pharmacogenomics

31.00M

15.82%

Tumor Profiling

29.30M

14.96%

股东统计

更新时间: 8月19日周二

持股股东

股东类型

持股股东

占比

BlackRock Institutional Trust Company, N.A.

14.43%

The Vanguard Group, Inc.

9.83%

Millennium Management LLC

5.29%

State Street Global Advisors (US)

5.17%

Glenview Capital Management, LLC

4.93%

其他

60.34%

持股股东

占比

BlackRock Institutional Trust Company, N.A.

14.43%

The Vanguard Group, Inc.

9.83%

Millennium Management LLC

5.29%

State Street Global Advisors (US)

5.17%

Glenview Capital Management, LLC

4.93%

其他

60.34%

股东类型

持股股东

占比

Investment Advisor

37.35%

Hedge Fund

27.45%

Investment Advisor/Hedge Fund

24.82%

Research Firm

6.02%

Individual Investor

3.32%

Pension Fund

1.90%

Bank and Trust

0.41%

Venture Capital

0.31%

Family Office

0.08%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

518

100.80M

108.34%

-1.85M

2025Q1

527

99.14M

107.57%

-4.54M

2024Q4

516

96.89M

106.12%

-1.41M

2024Q3

505

95.02M

104.61%

-5.50M

2024Q2

486

96.79M

106.52%

-6.22M

2024Q1

460

98.19M

108.68%

+613.48K

2023Q4

464

93.46M

105.77%

+2.70M

2023Q3

471

86.01M

104.78%

-3.73M

2023Q2

480

84.60M

103.32%

-6.34M

2023Q1

483

85.87M

105.37%

-2.69M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

BlackRock Institutional Trust Company, N.A.

13.85M

15.02%

-471.44K

-3.29%

Mar 31, 2025

The Vanguard Group, Inc.

10.62M

11.52%

+47.03K

+0.44%

Mar 31, 2025

Millennium Management LLC

4.07M

4.41%

-275.67K

-6.34%

Mar 31, 2025

State Street Global Advisors (US)

5.27M

5.72%

-256.92K

-4.65%

Mar 31, 2025

Glenview Capital Management, LLC

3.90M

4.23%

-257.77K

-6.20%

Mar 31, 2025

D. E. Shaw & Co., L.P.

2.52M

2.74%

+702.80K

+38.62%

Mar 31, 2025

Morgan Stanley & Co. LLC

1.41M

1.52%

+434.87K

+44.81%

Mar 31, 2025

Geode Capital Management, L.L.C.

2.23M

2.42%

+87.90K

+4.10%

Mar 31, 2025

Dimensional Fund Advisors, L.P.

2.21M

2.4%

-59.15K

-2.60%

Mar 31, 2025

Qube Research & Technologies Ltd

1.42M

1.54%

+416.78K

+41.62%

Mar 31, 2025

持股ETF

更新时间: 9月6日周六

机构名称

占比

Invesco NASDAQ Future Gen 200 ETF

0.66%

WisdomTree BioRevolution Fund

0.45%

Invesco S&P SmallCap Health Care ETF

0.44%

Inspire Small/Mid Cap ESG ETF

0.24%

SPDR S&P Biotech ETF

0.18%

Vanguard US Quality Factor ETF

0.12%

Direxion Daily S&P Biotech Bull 3X Shares

0.1%

iShares S&P Small-Cap 600 Value ETF

0.09%

SPDR S&P 600 Small Cap Value ETF

0.09%

Invesco S&P SmallCap 600 Revenue ETF

0.07%

Invesco NASDAQ Future Gen 200 ETF

占比0.66%

WisdomTree BioRevolution Fund

占比0.45%

Invesco S&P SmallCap Health Care ETF

占比0.44%

Inspire Small/Mid Cap ESG ETF

占比0.24%

SPDR S&P Biotech ETF

占比0.18%

Vanguard US Quality Factor ETF

占比0.12%

Direxion Daily S&P Biotech Bull 3X Shares

占比0.1%

iShares S&P Small-Cap 600 Value ETF

占比0.09%

SPDR S&P 600 Small Cap Value ETF

占比0.09%

Invesco S&P SmallCap 600 Revenue ETF

占比0.07%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Myriad Genetics Inc

7.680USD

Myriad Genetics Inc

7.680

概览

公司

财务

分析